The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Oct 17, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Care Tracker Study is looking at how we can better understand and address delays in cancer treatment, especially for patients of different races. This study will use a simple electronic tool for patients to report any issues they may face that could slow down their treatment. By collecting this information, along with data from medical records, researchers hope to identify patients at risk of delays and find ways to help them start their treatment sooner. The ultimate goal is to alert healthcare teams when a patient might be facing treatment delays, ensuring they receive the care they need as quickly as possible.
To participate in this study, you must be at least 18 years old and have been diagnosed with breast or colorectal cancer within the last six weeks. You should not have started any cancer treatment yet and need to plan to receive treatment at the University of North Carolina. Participants will be asked to complete brief surveys on their experiences and any potential barriers they might face. It's important that you can receive these surveys electronically, either via email or text message, and can understand English. If you're interested and meet these criteria, this study could be a great opportunity to help improve cancer care for everyone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
- • 1. Male and female patients of age \>18 years.
- • 2. Pathologic diagnosis of breasts or colorectal cancer within 6 weeks (42 days) prior to the enrollment date.
- • 3. Have not yet initiated cancer treatment on the date of enrollment.
- • 4. Indicate intent to receive cancer treatment at the University of North Carolina.
- Exclusion Criteria:
- • 1. Patient unwilling or unable to receive electronic survey links via email or text link on a mobile device, tablet, laptop, or desktop computer.
- • 2. Patient unwilling or unable to provide verbal or signed consent to participate.
- • 3. Patient cannot read and speak English.
- • 4. Patients who do not have email access or a smartphone are able to receive Short Message/Messaging Service (SMS) text messages.
About Unc Lineberger Comprehensive Cancer Center
The UNC Lineberger Comprehensive Cancer Center is a leading research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and comprehensive patient care. As a National Cancer Institute-designated comprehensive cancer center, it integrates cutting-edge research, interdisciplinary collaboration, and patient-centered approaches to address diverse oncology challenges. With a commitment to translating scientific discoveries into effective therapies, UNC Lineberger strives to improve outcomes for patients while fostering a robust environment for education and training in cancer research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chapel Hill, North Carolina, United States
Chapel Hill, North Carolina, United States
Patients applied
Trial Officials
Katie Reeder-Hayes
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported